메뉴 건너뛰기




Volumn 16, Issue 6, 2011, Pages 904-911

Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: Results from an internet-based survey

Author keywords

Health survey; Myelodysplastic syndromes; Patient reported outcomes; Treatment outcome

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; LENALIDOMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; THYMOCYTE ANTIBODY;

EID: 79959586108     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0199     Document Type: Article
Times cited : (55)

References (23)
  • 1
    • 34247646400 scopus 로고    scopus 로고
    • The incidence and impact of thrombo-cytopenia in myelodysplastic syndromes
    • Kantarjian H, Giles F, List A et al. The incidence and impact of thrombo-cytopenia in myelodysplastic syndromes. Cancer 2007;109:1705-1714.
    • (2007) Cancer , vol.109 , pp. 1705-1714
    • Kantarjian, H.1    Giles, F.2    List, A.3
  • 2
    • 0030897009 scopus 로고    scopus 로고
    • International scoring system for evaluating prognosisin myelodysplastic syndromes
    • Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosisin myelodysplastic syndromes. Blood 1997;89:2079-2088.
    • (1997) Blood , vol.89 , pp. 2079-2088
    • Greenberg, P.1    Cox, C.2    Lebeau, M.M.3
  • 3
    • 34548219420 scopus 로고    scopus 로고
    • Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelo-dysplastic syndromes
    • Malcovati L, Germing U, Kuendgen A et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelo-dysplastic syndromes. J Clin Oncol 2007;25:3503-3510.
    • (2007) J Clin Oncol , vol.25 , pp. 3503-3510
    • Malcovati, L.1    Germing, U.2    Kuendgen, A.3
  • 4
    • 47249150213 scopus 로고    scopus 로고
    • Epidemiologyof myelodysplas-tic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs
    • Rollison DE, Howlader N, Smith MT et al. Epidemiologyof myelodysplas-tic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008;112:45-52.
    • (2008) Blood , vol.112 , pp. 45-52
    • Rollison, D.E.1    Howlader, N.2    Smith, M.T.3
  • 5
    • 34247172535 scopus 로고    scopus 로고
    • Myelodysplastic syndromes: Incidence and survival in the United States
    • Ma X, Does M, Raza A et al. Myelodysplastic syndromes: Incidence and survival in the United States. Cancer 2007;109:1536-1542.
    • (2007) Cancer , vol.109 , pp. 1536-1542
    • Ma, X.1    Does, M.2    Raza, A.3
  • 6
    • 77956397358 scopus 로고    scopus 로고
    • Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries
    • Goldberg SL, Chen E, Corral M et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol 2010;28:2847-2852.
    • (2010) J Clin Oncol , vol.28 , pp. 2847-2852
    • Goldberg, S.L.1    Chen, E.2    Corral, M.3
  • 7
    • 77950526605 scopus 로고    scopus 로고
    • The epidemiology of myelodysplastic syndromes
    • Sekeres MA. The epidemiology of myelodysplastic syndromes. Hematol Oncol Clin North Am 2010;24:287-294.
    • (2010) Hematol Oncol Clin North Am , vol.24 , pp. 287-294
    • Sekeres, M.A.1
  • 8
    • 55749114037 scopus 로고    scopus 로고
    • Characteristics of US patients with myelodysplastic syndromes: Results of six cross-sectional physician surveys
    • Sekeres MA, Schoonen WM, Kantarjian H et al. Characteristics of US patients with myelodysplastic syndromes: Results of six cross-sectional physician surveys. J Natl Cancer Inst 2008;100:1542-1551.
    • (2008) J Natl Cancer Inst , vol.100 , pp. 1542-1551
    • Sekeres, M.A.1    Schoonen, W.M.2    Kantarjian, H.3
  • 9
    • 13444256401 scopus 로고    scopus 로고
    • Efficacy of lenalidomide in myelodysplastic syndromes
    • List A, Kurtin S, Roe DJ et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549-557.
    • (2005) N Engl J Med , vol.352 , pp. 549-557
    • List, A.1    Kurtin, S.2    Roe, D.J.3
  • 10
    • 0037093195 scopus 로고    scopus 로고
    • Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B
    • Silverman LR, Demakos EP, Peterson BL et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. J Clin Oncol 2002;20:2429-2440.
    • (2002) J Clin Oncol , vol.20 , pp. 2429-2440
    • Silverman, L.R.1    Demakos, E.P.2    Peterson, B.L.3
  • 11
    • 33646071894 scopus 로고    scopus 로고
    • Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study
    • Kantarjian H, Issa JP, Rosenfeld CS et al. Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 2006;106:1794-1803.
    • (2006) Cancer , vol.106 , pp. 1794-1803
    • Kantarjian, H.1    Issa, J.P.2    Rosenfeld, C.S.3
  • 12
    • 0037541576 scopus 로고    scopus 로고
    • Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes
    • Jansen AJ, Essink-Bot ML, Beckers EA et al. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol 2003;121:270-274.
    • (2003) Br J Haematol , vol.121 , pp. 270-274
    • Jansen, A.J.1    Essink-Bot, M.L.2    Beckers, E.A.3
  • 13
    • 40049097939 scopus 로고    scopus 로고
    • Common troublesome symptoms and their impact on quality of life in patients with myelodysplas-tic syndromes (MDS): Results of a large internet-based survey
    • Steensma DP, Heptinstall KV, Johnson VM et al. Common troublesome symptoms and their impact on quality of life in patients with myelodysplas-tic syndromes (MDS): Results of a large internet-based survey. Leuk Res 2008;32:691-698.
    • (2008) Leuk Res , vol.32 , pp. 691-698
    • Steensma, D.P.1    Heptinstall, K.V.2    Johnson, V.M.3
  • 14
    • 71049152788 scopus 로고    scopus 로고
    • Valuation of transfusion-free living in MDS: Results of health utility interviews with patients
    • Szende A, Schaefer C, Goss TF et al. Valuation of transfusion-free living in MDS: Results of health utility interviews with patients. Health Qual Life Outcomes 2009;7:81.
    • (2009) Health Qual Life Outcomes , vol.7 , pp. 81
    • Szende, A.1    Schaefer, C.2    Goss, T.F.3
  • 15
    • 79959579120 scopus 로고    scopus 로고
    • Measuring Healthy Days
    • Centers for Disease Control and Prevention, Atlanta, GA: Centers for Disease Control and Prevention, accessed May 28, 2010
    • Centers for Disease Control and Prevention. Measuring Healthy Days. Population Assessment of Health-Related Quality ofLife. Atlanta, GA: Centers for Disease Control and Prevention, 2000. Available at http://www.cdc.gov/hrqol/pdfs/mhd.pdf, accessed May 28, 2010.
    • (2000) Population Assessment of Health-Related Quality OfLife
  • 16
    • 36049026124 scopus 로고    scopus 로고
    • Response rate and completeness of questionnaires: A randomized study of internet versus pa-per-and-pencil versions
    • Kongsved SM, Basnov M, Holm-Christensen K et al. Response rate and completeness of questionnaires: A randomized study of internet versus pa-per-and-pencil versions. J Med Internet Res 2007;9:e25.
    • (2007) J Med Internet Res , vol.e25 , pp. 9
    • Kongsved, S.M.1    Basnov, M.2    Holm-Christensen, K.3
  • 17
    • 62849104641 scopus 로고    scopus 로고
    • Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study
    • Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 2009;10:223-232.
    • (2009) Lancet Oncol , vol.10 , pp. 223-232
    • Fenaux, P.1    Mufti, G.J.2    Hellstrom-Lindberg, E.3
  • 18
    • 23044440179 scopus 로고    scopus 로고
    • Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF
    • Jädersten M, Montgomery SM, Dybedal I et al. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 2005; 106:803-811.
    • (2005) Blood , vol.106 , pp. 803-811
    • Jädersten, M.1    Montgomery, S.M.2    Dybedal, I.3
  • 19
    • 33947499579 scopus 로고    scopus 로고
    • Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes
    • Golshayan AR, Jin T, Maciejewski J et al. Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. Br J Haematol 2007;137:125-132.
    • (2007) Br J Haematol , vol.137 , pp. 125-132
    • Golshayan, A.R.1    Jin, T.2    Maciejewski, J.3
  • 20
    • 0023777523 scopus 로고
    • Cancer patients' perceptions of their disease and its treatment
    • Mackillop WJ, Stewart WE, Ginsburg AD et al. Cancer patients' perceptions of their disease and its treatment. Br J Cancer 1988;58:355-358.
    • (1988) Br J Cancer , vol.58 , pp. 355-358
    • Mackillop, W.J.1    Stewart, W.E.2    Ginsburg, A.D.3
  • 21
    • 0038352135 scopus 로고    scopus 로고
    • Perceptions of patients and physicians regarding phase I cancer clinical trials: Implications for physician-patient communication
    • Meropol NJ, Weinfurt KP, Burnett CB et al. Perceptions of patients and physicians regarding phase I cancer clinical trials: Implications for physician-patient communication. J Clin Oncol 2003;21:2589-2596.
    • (2003) J Clin Oncol , vol.21 , pp. 2589-2596
    • Meropol, N.J.1    Weinfurt, K.P.2    Burnett, C.B.3
  • 22
    • 79953734876 scopus 로고    scopus 로고
    • Correlates of quality of life-related outcomes in breast cancer patients participating in the Pathfinders pilot study
    • 2010 May 26 [Epub ahead of print]. DOI: 10.1002/ pon.1770
    • Smith SK, Herndon JE, Lyerly HK et al. Correlates of quality of life-related outcomes in breast cancer patients participating in the Pathfinders pilot study. Psychooncology 2010 May 26 [Epub ahead of print]. DOI: 10.1002/ pon.1770.
    • Psychooncology
    • Smith, S.K.1    Herndon, J.E.2    Lyerly, H.K.3
  • 23
    • 33750020532 scopus 로고    scopus 로고
    • South Thames Haematology Specialist Committee. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England
    • Phekoo KJ, Richards MA, Mller H et al.; South Thames Haematology Specialist Committee. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England. Haematologica 2006;91: 1400-1404.
    • (2006) Haematologica , vol.91 , pp. 1400-1404
    • Phekoo, K.J.1    Richards, M.A.2    Mller, H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.